Luca Gentile

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1412162/publications.pdf

Version: 2024-02-01

42	667	623734	610901
papers	citations	14 h-index	24 g-index

43	43	43	765
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	3.6	13
2	Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging. European Radiology, 2022, , 1.	4.5	1
3	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	3.3	13
4	Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 197-204.	3.0	5
5	Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 499-514.	0.7	8
6	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	3.6	38
7	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
8	Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sciences, 2021, 11, 515.	2.3	8
9	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy. Scientific Reports, 2021, 11, 9216.	3.3	3
10	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	2.3	17
11	Very Early Onset of ATTRE89Q Amyloidosis in a Homozygous Patient. The Open Neurology Journal, 2021, 15, 21-24.	0.4	0
12	The neurophysiological lesson from the Italian CIDP database. Neurological Sciences, 2021, , 1.	1.9	3
13	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	2.6	8
14	Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. Journal of Neurology, 2021, , 1.	3.6	1
15	Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. Archives of Medical Science, 2021, 18, 696-703.	0.9	3
16	Rare among Rare: Phenotypes of Uncommon CMT Genotypes. Brain Sciences, 2021, 11, 1616.	2.3	1
17	Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. Neurological Sciences, 2020, 41, 1239-1243.	1.9	16
18	Ultrasound guidance increases diagnostic yield of needle EMG in plegic muscle. Clinical Neurophysiology, 2020, 131, 446-450.	1.5	11

#	Article	IF	Citations
19	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
20	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	2.3	24
21	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1092-1099.	1.9	22
22	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences, 2020, 10, 952.	2.3	9
23	Impact of environmental factors and physical activity on disability and quality of life in CIDP. Journal of Neurology, 2020, 267, 2683-2691.	3.6	4
24	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	3.1	18
25	From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 279-280.	3.0	3
26	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 102.	2.9	11
27	Patients' and physicians' interpretation of chemotherapyâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 111-119.	3.1	20
28	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	1.9	32
29	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.6	14
30	Shear wave elastography of median nerve at wrist and forearm. Heterogeneity of normative values. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 137-171.	1.0	11
31	â€œSeeing Through the Wallâ€• Ultrasound Application for the Diagnosis and Treatment of Abdominal Pain. Pain Medicine, 2019, 20, 581-582.	1.9	1
32	â€œIt is not what it seems.â€•Ultrasound findings in a case of unusual iatrogenic ulnar nerve damage. Child's Nervous System, 2019, 35, 201-203.	1.1	0
33	Unilateral hyperhidrosis as persistently isolated feature of syringomyelia and Arnold Chiari type 1. Neurological Sciences, 2018, 39, 1607-1608.	1.9	3
34	A Cyst Compressing the Ulnar Nerve Motor Branch. Annals of Plastic Surgery, 2018, 81, 124-125.	0.9	0
35	Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart. Neurological Sciences, 2017, 38, 525-526.	1.9	15
36	Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 791-793.	1.9	37

#	Article	IF	Citations
37	Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. Journal of Neuromuscular Diseases, 2015, 2, S39-S48.	2.6	67
38	Charcotâ€“Marieâ€“Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family. Neurological Sciences, 2015, 36, 1003-1006.	1.9	18
39	Considerable post-partum worsening in a patient with CMT2E. Neurological Sciences, 2013, 34, 1813-1814.	1.9	1
40	Transthyretinâ€related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. Journal of the Peripheral Nervous System, 2012, 17, 385-390.	3.1	41
41	Unusual features of central nervous system involvement in <scp>CMTX</scp> associated with a novel mutation of <scp>GJB1</scp> gene. Journal of the Peripheral Nervous System, 2012, 17, 407-411.	3.1	13
42	Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle and Nerve, 2012, 45, 451-452.	2.2	10